Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

Authors Alex C Spyropoulos, Sharyl Magnuson, Sei Keng Koh

Published 6 June 2008 Volume 2008:4(3) Pages 653—657

DOI https://doi.org/10.2147/TCRM.S2633

Alex C Spyropoulos1, Sharyl Magnuson1, Sei Keng Koh2

1Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM, USA; 2Department of Pharmacy, Singapore General Hospital, Singapore

Abstract: Heparin-induced thrombocytopenia (HIT) is an immunologic drug reaction characterized by paradoxical association with venous and arterial thrombosis. The syndrome is caused by IgG antibodies that are reactive against complexes of platelet factor 4 and heparin. Fondparinux does not bind to platelet factor 4, is structurally too short to induce an antibody response, and could in theory be a useful agent to treat HIT. A 69-year-old white female presented with a lower extremity extensive iliofemoral deep vein thrombosis after a right total knee arthroplasty and was subsequently found to have a pulmonary embolism. The patient was noted to have heparin flushes during her operation. Her platelet drop decreased >50% from baseline during initiation of antithrombotic therapy. She was started on subcutaneous fondaparinux 7.5 mg once daily injection. Her serotonin release assay and enzyme-linked immunosorbent assay for heparin antibodies were positive for HIT. Her platelet count nadir was 60 × 103/mm3 on day 5 and the platelet count rebounded after 8 days of fondaparinux therapy. No recurrent thrombotic or bleeding events were noted throughout her therapy. Anecdotal reports have shown that fondaparinux can be a useful agent to treat HIT with or without thrombosis.

Keywords: fondaparinux, heparin-induced thrombocytopenia with thrombosis (HITT)

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A characteristic optic disc appearance associated with myopia in subjects with Graves' ophthalmopathy and in subjects with primary open-angle glaucoma

Yamazaki S, Inoue R, Tsuboi T, Kozaki A, Inoue T, Inoue T, Inoue Y

Clinical Ophthalmology 2013, 7:47-53

Published Date: 7 January 2013

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Debra L Breneman, Timothy J Storer, John C Breneman, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:1135-1141

Published Date: 10 October 2008

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Bianca Devitt, Sue-Anne McLachlan

Therapeutics and Clinical Risk Management 2008, 4:453-458

Published Date: 11 April 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:335-336

Published Date: 15 December 2006

A review of studies of adherence with antihypertensive drugs using prescription databases

Nicola Fitz-Simon, Kathleen Bennett, John Feely

Therapeutics and Clinical Risk Management 2005, 1:93-106

Published Date: 15 July 2005